Results 141 to 150 of about 757 (186)

Frequent Use of Premenopausal Progestin in Women With Prior Preeclampsia.

J Clin Endocrinol Metab
Joensuu JM, Ylikorkala O, Venetkoski M, Gissler M, Savolainen-Peltonen H, Mikkola TS.   +5 more
europepmc   +1 more source

Fertility Sparing in Endometrial Cancer: Where Are We Now? [PDF]

Cancers (Basel)
Centini G, Colombi I, Ianes I, Perelli F, Ginetti A, Cannoni A, Habib N, Negre RR, Martire FG, Raimondo D, Lazzeri L, Zupi E.   +11 more
europepmc   +1 more source

Use of PROMIS Global-10 to measure changes in health-related quality of life among contraceptive initiators: A feasibility study. [PDF]

Contraception
Barker ES, Paul R, Dorsey M, Reeves JA, Madden T.   +4 more
europepmc   +1 more source

Preventing recurrence of endometriosis-related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT.

Health Technol Assess
Cooper KG, Bhattacharya S, Daniels JP, Cheed V, Gennard L, Leighton L, Pirie D, Melyda M, Monahan M, Weckesser A, Roberts T, Denny E, Ocansey L, Stubbs C, Cox E, Jones G, Clark TJ, Saridogan E, Gupta JK, Critchley HO, Horne A, Middleton LJ.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Intrauterine Devices: Medicated and Nonmedicated

International Journal of Gynecology and Obstetrics, 1979
The main benefits of intrauterine devices (IUDs) are a lack of adverse systemic effects, excellent effectiveness, high continuation rates and the single act of motivation required for use. First year failure rates range from 2% to 3%, but decline steadily thereafter to a cumulative annual failure rate of less than 1% after six years.
D R Mishell
exaly   +3 more sources

Medicated intrauterine devices for contraception and their therapeutic effects

Expert Review of Obstetrics and Gynecology, 2006
There is currently one medicated intrauterine device on the market for clinical use; Mirena®, which releases levonorgestel. Mirena has widely replaced Progestasert®, which released progesterone. The levonorgestel released by Mirena into the uterine cavity not only increases the contraceptive efficacy of the intrauterine device but also has many ...
Päivi Pakarinen, Tapani Luukkainen
exaly   +2 more sources

Experience with Two Different Medicated Intrauterine Devices: A Comparative Study of the Progestasert and Nova-T

Fertility and Sterility, 1979
A comparative study of the Progestasert (UPS) and the Nova-T in 326 randomly selected women was carried out. The observation period was 1 year. The over-all continuation rates for the two types of intrauterine devices (IUDs) were similar. The expulsion rate for the Nova-T (9.2%) was considerably higher (P = 0.001) than that for the UPS (1.2%).
P, Fylling, M, Fagerhol
exaly   +3 more sources

Medicated Intrauterine Devices

1980
exaly   +2 more sources

Intrauterine device insertion after medical abortion

Contraception, 2011
Studies comparing immediate intrauterine device (IUD) insertion after first-trimester surgical abortion with interval insertion show similar efficacy and expulsion rates. However, women randomized to interval insertion of an IUD are less likely to return for device placement.
Sarah J, Betstadt, David K, Turok, Nathalie, Kapp, Kui-Tzu, Feng, Lynn, Borgatta   +4 more
openaire   +2 more sources